EDP-305 clinical trials
Also written EDP-305.
- studies test it
- 10
- open now
- 0
- in phase 3
- 0
- first study started
- 2016
How each study uses EDP-305 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- EDP-305
- 8
Studies by the year they started
10 studies that test it; most in 2017 (4)
| Year | Studies |
|---|---|
| 2016 | 1 |
| 2017 | 4 |
| 2018 | 4 |
| 2020 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 10 · Other 0
Often tested with
Tested in the same studies.
Contraceptives, Oral (1)
Studies
Open first, then newest update. How each study uses EDP-305 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 10
- A Randomized, Double-blind Study to Assess the Safety and Efficacy of EDP-305 in Subjects With Liver-biopsy Proven NASHTerminatedPhase 2Enanta Pharmaceuticals, IncNCT04378010Written as EDP-305 1.5 mg
- A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Non-Alcoholic SteatohepatitisCompletedPhase 2Enanta Pharmaceuticals, IncNCT03421431Written as EDP-305 Dose 1
- A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Primary Biliary CholangitisCompletedPhase 2Enanta Pharmaceuticals, IncNCT03394924Written as EDP-305 1 mg
- A Drug-drug Interaction Study to Investigate the Effect of Coadministration of EDP-305 on the PK of a Combined Oral Contraceptive in Healthy Female SubjectsCompletedPhase 1Enanta Pharmaceuticals, IncNCT03783897Written as EDP-305
- Drug-drug Interaction Study Between EDP-305, Fluconazole and Quinidine in Healthy VolunteersCompletedPhase 1Enanta Pharmaceuticals, IncNCT03610945Written as EDP-305
- Absorption, Metabolism and Excretion (AME) Study of [14C]EDP-305 in Healthy Male SubjectsCompletedPhase 1Enanta Pharmaceuticals, IncNCT03748628Written as EDP-305
- A Study of EDP-305 in Subjects With Mild and Moderate Hepatic Impairment Compared With Normal Healthy VolunteersCompletedPhase 1Enanta Pharmaceuticals, IncNCT03207425Written as EDP 305
- Drug-drug Interaction Study Between EDP-305, Intraconazole and Rifampin in Healthy VolunteersCompletedPhase 1Enanta Pharmaceuticals, IncNCT03213145Written as EDP 305
- A Study of EDP 305 in Healthy Subjects and Subjects With Presumptive NAFLDCompletedPhase 1Enanta Pharmaceuticals, IncNCT02918929Written as EDP 305
- Drug-drug Interaction Study Between EDP-305, Midazolam, Caffeine and Rosuvastatin in Healthy Volunteers.CompletedPhase 1Enanta Pharmaceuticals, IncNCT03187496Written as EDP-305
Codes
What other systems call EDP-305 · ClinicalTrials.gg INT001386
- Wikidata Q123907234EDP-305One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| Wikidata | Q123907234 | EDP-305 | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.